http://www.aktiencheck.de aktiencheck.de aktiencheck.de Fri, 24 Apr 2026 10:36:58 +0200 2 http://www.aktiencheck.de/forum/Wohin_fuehrt_der_Weg-A0JMQD-t342480 http://www.aktiencheck.de/forum/Wohin_fuehrt_der_Weg-A0JMQD-t342480 Micromet drug helps 75 pct of leukaemia patients, (Reuters) - An experimental drug from Micromet (MITI.O) reduced levels of cancer cells to undetectable levels in nine out of 12 patients with a severe form of leukaemia, interim data from a clinical study showed on Friday. Blinatumomab is a new kind of antibody drug that primes the body's own killer T-cells to directly attack tumour cells. The 75 percent response rate represented a boost for the Maryland-based company's first product, which is still several years away from reaching market but has been attracting attention from scientists because of the novel way it works. The Phase II study is due to enroll 25 adults with acute lymphoblastic leukaemia (ALL) who have previously relapsed after standard chemotherapy. Interim results from the first 12 patients were unveiled at a medical congress in London. ALL is a relatively rare cancer in which malignant immature white blood cells are overproduced and crowd out normal cells in [<a href="http://www.aktiencheck.de/forum/Wohin_fuehrt_der_Weg-A0JMQD-t342480">mehr</a>]